IP Library Granted Patent US 8,541,192
Granted Patent B2
US 8,541,192 · App. 12/835,559 · Granted Sep 24, 2013

Methods to identify USP1 deubiquitinating enzyme complex inhibitors

Inventor: Alan D. D'Andrea (Winchester, MA)
Assignee: Dana-Farber Cancer Institute, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,541,192
App. No.
12/835,559
Granted
Sep 24, 2013
Kind
B2
Abstract

The invention provides methods used to identify new inhibitors of USP1 deubiquitinase. The inhibitors can be identified by contacting isolated USP1 with a test compound in the presence of monoubiquitinated proliferating cell nuclear antigen (PCNA), monoubiquitinated human Fanconi anemia group D2 (FANCD2), or ubiquitin-7-amido-4-methylcoumarin, and detecting the deubiquitination of said PCNA, FANCD2, or ubiquitin-7-amido-4-methylcoumarin using an antibody or fluorescence, wherein a decrease in the deubiquitination of said PCNA, FANCD2, or ubiquitin-7-amido-4-methylcoumarin in the presence of the test compound relative to the absence of the test compound identifies said test compound as an inhibitor of USP1 deubiquitinase.

Claims (12)

1. An in vitro, biochemical method of identifying an inhibitor of ubiquitin specific protease 1(USP1) comprising:

(i) contacting an isolated USP1 with a test compound in the presence of monoubiquitinated proliferating cell nuclear antigen (PCNA) or ubiquitin-7-amido-4-methylcoumarin,

wherein said USP1 is selected from the group consisting of SEQ ID NO: 3 or the polypeptide set forth by amino acids 17-785 of SEQ ID NO: 3, and wherein said PCNA comprises SEQ ID NO: 2; and

(ii) detecting the deubiquitination of said PCNA or ubiquitin-7-amido-4-methylcoumarin using an antibody or fluorescence,

wherein a decrease in the deubiquitination of said PCNA or ubiquitin-7-amido-4-methylcoumarin in the presence of the test compound, relative to the absence of the test compound, identifies said test compound as an inhibitor of USP1.

2. The method of claim 1 , wherein USP1 is present in a heterodimeric complex with human USP1 associated factor 1 (UAF1).

3. An in vitro, biochemical method of identifying an inhibitor of USP1 comprising:

(i) contacting a composition comprising isolated USP1 and isolated human UAF1 with a test compound in the presence of ubiquitin-7-amido-4-methylcoumarin,

wherein said USP1 is selected from the group consisting of SEQ ID NO: 3 or the polypeptide set forth by amino acids 17-785 of SEQ ID NO: 3, and

(ii) detecting the deubiquitination of said ubiquitin-7-amido-4- methylcoumarin using fluorescence,

wherein a decrease in the deubiquitination of said ubiquitin-7-amido-4- methylcoumarin in the presence of the test compound, relative to the absence of the test compound, identifies said test compound as an inhibitor of USP1.

4. The method of claim 3 , wherein said method is adapted to a high throughput screen.

Assignments (2)
CONFIRMATORY LICENSE Recorded Dec 5, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040807/0085 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2011
From: D'ANDREA, ALAN D.
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 025919/0586 →
Continuity (3)
Continuation 11820674 · Jun 20, 2007
Provisional Application 60815483 · Jun 20, 2006
Related Publication 20100330599A1 · Dec 30, 2010